Quick Answer
LakeShore Biopharma Co., Ltd. reported R&D Expense of $20.39 million for fiscal year 2025.
LakeShore Biopharma Co., Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $20.39M | -93.3% |
| 2024 | $302.80M | -5.0% |
| 2023 | $318.70M | +50.9% |
| 2022 | $211.22M | +123.8% |
| 2021 | $94.39M | — |
- LakeShore Biopharma Co., Ltd. showed a decrease of -93.3% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, LakeShore Biopharma Co., Ltd.’s r&d expense has declined by 78.4% (from $94.39 million to $20.39 million).
- The most recent figure is from LakeShore Biopharma Co., Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on July 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: